Small molecule · Inhibitor of MEK1 (MAP2K1) (MAP2K1) and MEK2 (MAP2K2) (MAP2K2) · developed by Recursion Pharmaceuticals
REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small-molecule inhibitor of MEK1 and MEK2 kinases. It binds these enzymes to block activation of the RAS/RAF/MEK/ERK pathway and tumor cell proliferation. It is being studied in familial adenomatous polyposis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05552755 | Phase 1/2 | Familial Adenomatous Polyposis | Recruiting | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Familial Adenomatous Polyposis
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →